Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

NCT03735966 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

OTHER_GOV

Sponsor class

Conditions

HER2 Positive Breast Cancer

Interventions

DRUG: Pyrotinib plus trastuzumab and docetaxel and carboplatin

Sponsor

Henan Cancer Hospital